Guangzhou panel test for early colorectal cancer recurrence
Part of Cancer, Digestive system clinical trials.
This study looks at past records of people with early-stage colorectal cancer to see if a special test called the Guangzhou Panel can help predict whether the cancer will come back. It may help doctors better understand who needs extra treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage I or II colorectal cancer (meaning the tumor has not spread to lymph nodes or distant organs).
- You had surgery to remove the tumor completely.
- You have a stored tumor sample from surgery.
- You had specific genetic tests on the tumor (like BRAF, KRAS, MSI, and CIMP).
- You have been followed for at least 4 years after surgery (this trial looks at past records).
- You have not had any other cancer diagnosis, do not have inflammatory bowel disease, and do not have a known hereditary colorectal cancer syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (liquid biopsy) to look for tiny bits of cancer DNA remaining after surgery. It aims to see if this test can help guide follow-up and treatment decisions for people with colorectal cancer.
This trial tests a new stool-based screening test that may find colorectal cancer and advanced adenomas (precancerous growths) early. It studies whether the test works well compared with the standard colonoscopy, so it could offer an easier, less invasive screening option in the future.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This study is testing a new way to detect colorectal cancer early by looking for specific changes (gene methylation) in stool and blood samples. If you are 40 or older and have a colonoscopy scheduled, this non-invasive approach might help find cancer sooner.
This study looks at metabolic biomarkers in blood and tumor tissue to help detect colorectal cancer earlier, predict outcomes, and monitor for recurrence. It includes both people newly diagnosed with colorectal cancer and healthy volunteers for comparison.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.